ArticleHeart rhythm O22026
Atrial electrogram amplitude-guided Bachmann bundle pacing implantation: A single-center experience.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bachmann bundle pacing (BBp) seems to be associated with reduced incidence and persistence of atrial fibrillation. The Bachmann bundle area is located at the junction between the superior vena cava and the right atrium. Pacemaker leads were implanted just inferior to a site demonstrating an abrupt increase in electrogram amplitude as the lead delivery system was advanced inferoseptally from the superior vena cava toward the right atrium as long as adequate sensing and capture thresholds were demonstrated. Subsequent to the implant, paced P waves were evaluated for evidence of Bachmann bundle capture. Objective: This study aimed to evaluate the feasibility, safety, and short-term outcomes of an atrial electrogram amplitude-guided implantation strategy for BBp. Methods: We retrospectively included 50 patients who underwent dual-chamber pacemaker or implantable cardioverter-defibrillator implantation with attempted BBp between September 2023 and December 2024. The atrial pacing lead was fixed just below the site demonstrating an abrupt change in atrial electrogram amplitude, typically exceeding 1 mV. Results: Atrial septal lead implantation was achieved in all patients, with successful BBp (meeting electrocardiogram criteria) in 44 (88%). The median mapping time was 134.5 seconds. Immediately after fixing the lead, the mean capture threshold was 1.86 ± 1.00 V at 0.4 ms, improving to 0.834 ± 0.315 V by the end of the procedure. During the 6-month follow-up, pacing parameters remained stable, with no lead dislodgement, pericardial effusion, or device-related infection. Conclusion: BBp using the lumenless pacing lead and delivery catheter, guided by an atrial electrogram amplitude-based strategy, is safe, feasible, and reproducible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.